[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$97share](/topic/$97share) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "ðĒM&A News: Novo Nordisk to acquire Akero Therapeutics for up to $5.2B ðĻ ð° $54/share cash + $6/share CVR tied to FDA approval of efruxifermin for MASH cirrhosis ð XX% premium to Akeros pre-deal price 𧎠Adds Phase X FGF21 analog EFX to Novos metabolic portfolio ð Deal closes by YE 2025 pending approvals ðĪ Signals renewed M&A momentum in MASH/NASH. Validates FGF21 pathway.potential re-rating for peers like $VKTX $TERN See image for more details" [X Link](https://x.com/BiopharmIQ/status/1976303356961550704) [@BiopharmIQ](/creator/x/BiopharmIQ) 2025-10-09T15:06Z 27.4K followers, 16K engagements "ðĨ $GMAB soars X% after announcing $8B acquisition of Merus. Deal includes $97/share cash offer for Netherlands-based biotech firm. Analysts bullish: Truist maintains Buy rating ($46 PT) TD Cowen raises PT to $XX from $XX. Acquisition expected to close Q1 2026. @grok" [X Link](https://x.com/CryptoMilox/status/1973113259797442681) [@CryptoMilox](/creator/x/CryptoMilox) 2025-09-30T19:50Z 1075 followers, XXX engagements "ðĒ M&A News: Genmab $GMAB to acquire Merus $MRUS for $8B ð° $97/share all-cash (41% premium $8B EV) 𧎠Adds Phase X bispecific petosemtamab (BTD in head & neck cancer) Ph2 data showed strong ORR & PFS SOC; Ph3 readouts in 2026 Expected launch 2027 $1B sales by 2029 multi-billion potential longer term ð Closing by Q1 2026 See photo for more info ð" [X Link](https://x.com/BiopharmIQ/status/1972672796154355942) [@BiopharmIQ](/creator/x/BiopharmIQ) 2025-09-29T14:40Z 27.4K followers, 10.4K engagements "Biotech Movers & News ð§Žð ðđ $DWTX Dogwood Therapeutics acquires global rights to Serpin Pharmas SP16 (7.31% equity). NCI-funded Phase 1b in CIPN starts 1H26. Synergistic with Halneuron (Phase 2b interim data Dec 2025). ðđ $GMAB Genmab to buy Merus ($MRUS) for $8B cash ($97/share) adding Phase X petosemtamab. Boosts late-stage oncology pipeline & 2027 launches. ðđ $RDHL RedHill wins $10M appellate judgment vs. Kukbo + Korean court asset seizure order" [X Link](https://x.com/AnunTrades/status/1972654562386571711) [@AnunTrades](/creator/x/AnunTrades) 2025-09-29T13:27Z 6712 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"ðĒM&A News: Novo Nordisk to acquire Akero Therapeutics for up to $5.2B ðĻ ð° $54/share cash + $6/share CVR tied to FDA approval of efruxifermin for MASH cirrhosis ð XX% premium to Akeros pre-deal price 𧎠Adds Phase X FGF21 analog EFX to Novos metabolic portfolio ð Deal closes by YE 2025 pending approvals ðĪ Signals renewed M&A momentum in MASH/NASH. Validates FGF21 pathway.potential re-rating for peers like $VKTX $TERN See image for more details"
X Link @BiopharmIQ 2025-10-09T15:06Z 27.4K followers, 16K engagements
"ðĨ $GMAB soars X% after announcing $8B acquisition of Merus. Deal includes $97/share cash offer for Netherlands-based biotech firm. Analysts bullish: Truist maintains Buy rating ($46 PT) TD Cowen raises PT to $XX from $XX. Acquisition expected to close Q1 2026. @grok"
X Link @CryptoMilox 2025-09-30T19:50Z 1075 followers, XXX engagements
"ðĒ M&A News: Genmab $GMAB to acquire Merus $MRUS for $8B ð° $97/share all-cash (41% premium $8B EV) 𧎠Adds Phase X bispecific petosemtamab (BTD in head & neck cancer) Ph2 data showed strong ORR & PFS SOC; Ph3 readouts in 2026 Expected launch 2027 $1B sales by 2029 multi-billion potential longer term ð Closing by Q1 2026 See photo for more info ð"
X Link @BiopharmIQ 2025-09-29T14:40Z 27.4K followers, 10.4K engagements
"Biotech Movers & News ð§Žð ðđ $DWTX Dogwood Therapeutics acquires global rights to Serpin Pharmas SP16 (7.31% equity). NCI-funded Phase 1b in CIPN starts 1H26. Synergistic with Halneuron (Phase 2b interim data Dec 2025). ðđ $GMAB Genmab to buy Merus ($MRUS) for $8B cash ($97/share) adding Phase X petosemtamab. Boosts late-stage oncology pipeline & 2027 launches. ðđ $RDHL RedHill wins $10M appellate judgment vs. Kukbo + Korean court asset seizure order"
X Link @AnunTrades 2025-09-29T13:27Z 6712 followers, XXX engagements
/topic/$97share/posts